A citation-based method for searching scientific literature

Philip Mease, Stephen Hall, Oliver FitzGerald, Désirée van der Heijde, Joseph F Merola, Francisco Avila-Zapata, Dorota Cieślak, Daniela Graham, Cunshan Wang, Sujatha Menon, Thijs Hendrikx, Keith S Kanik. N Engl J Med 2017
Times Cited: 268







List of co-cited articles
880 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Dafna Gladman, William Rigby, Valderilio F Azevedo, Frank Behrens, Ricardo Blanco, Andrzej Kaszuba, Elizabeth Kudlacz, Cunshan Wang, Sujatha Menon, Thijs Hendrikx,[...]. N Engl J Med 2017
253
66

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Philip Mease, Laura C Coates, Philip S Helliwell, Mykola Stanislavchuk, Anna Rychlewska-Hanczewska, Anna Dudek, Walid Abi-Saab, Chantal Tasset, Luc Meuleners, Pille Harrison,[...]. Lancet 2018
102
28

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, Maarten de Wit, Iain McInnes, Maxime Dougados, Jette Primdahl, Dennis G McGonagle, Daniel Aletaha, Andra Balanescu,[...]. Ann Rheum Dis 2020
295
27

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
Iain B McInnes, Arthur Kavanaugh, Alice B Gottlieb, Lluís Puig, Proton Rahman, Christopher Ritchlin, Carrie Brodmerkel, Shu Li, Yuhua Wang, Alan M Mendelsohn,[...]. Lancet 2013
525
24

Psoriatic Arthritis.
Christopher T Ritchlin, Robert A Colbert, Dafna D Gladman. N Engl J Med 2017
603
22

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Philip J Mease, Désirée van der Heijde, Christopher T Ritchlin, Masato Okada, Raquel S Cuchacovich, Catherine L Shuler, Chen-Yen Lin, Daniel K Braun, Chin H Lee, Dafna D Gladman. Ann Rheum Dis 2017
313
22

Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
Iain B McInnes, Jaclyn K Anderson, Marina Magrey, Joseph F Merola, Yi Liu, Mitsumasa Kishimoto, Slawomir Jeka, Cesar Pacheco-Tena, Xin Wang, Liang Chen,[...]. N Engl J Med 2021
51
43

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.
Désirée van der Heijde, Atul Deodhar, James C Wei, Edit Drescher, Dona Fleishaker, Thijs Hendrikx, David Li, Sujatha Menon, Keith S Kanik. Ann Rheum Dis 2017
194
20


Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.
Laura C Coates, Arthur Kavanaugh, Philip J Mease, Enrique R Soriano, Maria Laura Acosta-Felquer, April W Armstrong, Wilson Bautista-Molano, Wolf-Henning Boehncke, Willemina Campbell, Alberto Cauli,[...]. Arthritis Rheumatol 2016
533
19

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Atul Deodhar, Philip S Helliwell, Wolf-Henning Boehncke, Alexa P Kollmeier, Elizabeth C Hsia, Ramanand A Subramanian, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou,[...]. Lancet 2020
108
19

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.
Désirée van der Heijde, In-Ho Song, Aileen L Pangan, Atul Deodhar, Filip van den Bosch, Walter P Maksymowych, Tae-Hwan Kim, Mitsumasa Kishimoto, Andrea Everding, Yunxia Sui,[...]. Lancet 2019
111
18

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.
Roy Fleischmann, Joel Kremer, John Cush, Hendrik Schulze-Koops, Carol A Connell, John D Bradley, David Gruben, Gene V Wallenstein, Samuel H Zwillich, Keith S Kanik. N Engl J Med 2012
636
18

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).
P J Mease, R Fleischmann, A A Deodhar, J Wollenhaupt, M Khraishi, D Kielar, F Woltering, C Stach, B Hoepken, T Arledge,[...]. Ann Rheum Dis 2014
308
18

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
Philip J Mease, Proton Rahman, Alice B Gottlieb, Alexa P Kollmeier, Elizabeth C Hsia, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Yanli Zhuang,[...]. Lancet 2020
106
18

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
Philip J Mease, Dafna D Gladman, Christopher T Ritchlin, Eric M Ruderman, Serge D Steinfeld, Ernest H S Choy, John T Sharp, Peter A Ory, Renee J Perdok, Mark A Weinberg. Arthritis Rheum 2005
685
18

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.
Philip J Mease, Apinya Lertratanakul, Jaclyn K Anderson, Kim Papp, Filip Van den Bosch, Shigeyoshi Tsuji, Eva Dokoupilova, Mauro Keiserman, Xin Wang, Sheng Zhong,[...]. Ann Rheum Dis 2021
56
32

Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
Ronald F van Vollenhoven, Roy Fleischmann, Stanley Cohen, Eun Bong Lee, Juan A García Meijide, Sylke Wagner, Sarka Forejtova, Samuel H Zwillich, David Gruben, Tamas Koncz,[...]. N Engl J Med 2012
620
17

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
William J Sandborn, Chinyu Su, Bruce E Sands, Geert R D'Haens, Séverine Vermeire, Stefan Schreiber, Silvio Danese, Brian G Feagan, Walter Reinisch, Wojciech Niezychowski,[...]. N Engl J Med 2017
725
17

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd-Ruediger Burmester, David H Adams, Lisa Kerr, Chin Lee, Catherine L Shuler,[...]. Lancet 2017
224
17

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
C Antoni, G G Krueger, K de Vlam, C Birbara, A Beutler, C Guzzo, B Zhou, L T Dooley, A Kavanaugh. Ann Rheum Dis 2005
523
17

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
K A Papp, M A Menter, M Abe, B Elewski, S R Feldman, A B Gottlieb, R Langley, T Luger, D Thaci, M Buonanno,[...]. Br J Dermatol 2015
192
16

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
Désirée van der Heijde, Xenofon Baraliakos, Lianne S Gensler, Walter P Maksymowych, Vira Tseluyko, Oleg Nadashkevich, Walid Abi-Saab, Chantal Tasset, Luc Meuleners, Robin Besuyen,[...]. Lancet 2018
132
16

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
Arthur Kavanaugh, Iain McInnes, Philip Mease, Gerald G Krueger, Dafna Gladman, Juan Gomez-Reino, Kim Papp, Julie Zrubek, Surekha Mudivarthy, Michael Mack,[...]. Arthritis Rheum 2009
447
16

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
Arthur Kavanaugh, Philip J Mease, Juan J Gomez-Reino, Adewale O Adebajo, Jürgen Wollenhaupt, Dafna D Gladman, Eric Lespessailles, Stephen Hall, Marla Hochfeld, ChiaChi Hu,[...]. Ann Rheum Dis 2014
290
16

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.
Philip J Mease, Alan J Kivitz, Francis X Burch, Evan L Siegel, Stanley B Cohen, Peter Ory, David Salonen, Joel Rubenstein, John T Sharp, Wayne Tsuji. Arthritis Rheum 2004
689
15

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Iain B McInnes, Philip J Mease, Bruce Kirkham, Arthur Kavanaugh, Christopher T Ritchlin, Proton Rahman, Désirée van der Heijde, Robert Landewé, Philip G Conaghan, Alice B Gottlieb,[...]. Lancet 2015
530
15

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
Philip J Mease, Iain B McInnes, Bruce Kirkham, Arthur Kavanaugh, Proton Rahman, Désirée van der Heijde, Robert Landewé, Peter Nash, Luminita Pricop, Jiacheng Yuan,[...]. N Engl J Med 2015
495
15

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
Philip J Mease, Josef S Smolen, Frank Behrens, Peter Nash, Soyi Liu Leage, Lingnan Li, Hasan Tahir, Melinda Gooderham, Eswar Krishnan, Hong Liu-Seifert,[...]. Ann Rheum Dis 2020
112
14

Classification criteria for psoriatic arthritis: development of new criteria from a large international study.
William Taylor, Dafna Gladman, Philip Helliwell, Antonio Marchesoni, Philip Mease, Herman Mielants. Arthritis Rheum 2006
14

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
Philip Mease, Désirée van der Heijde, Robert Landewé, Shephard Mpofu, Proton Rahman, Hasan Tahir, Atul Singhal, Elke Boettcher, Sandra Navarra, Karin Meiser,[...]. Ann Rheum Dis 2018
147
14

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.
Jasvinder A Singh, Gordon Guyatt, Alexis Ogdie, Dafna D Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan Dunham, M Elaine Husni, Sarah Kenny,[...]. Arthritis Rheumatol 2019
185
14

Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
Joel Kremer, Zhan-Guo Li, Stephen Hall, Roy Fleischmann, Mark Genovese, Emilio Martin-Mola, John D Isaacs, David Gruben, Gene Wallenstein, Sriram Krishnaswami,[...]. Ann Intern Med 2013
310
13

Tofacitinib versus methotrexate in rheumatoid arthritis.
Eun Bong Lee, Roy Fleischmann, Stephen Hall, Bethanie Wilkinson, John D Bradley, David Gruben, Tamas Koncz, Sriram Krishnaswami, Gene V Wallenstein, Chuanbo Zang,[...]. N Engl J Med 2014
474
13

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Hervé Bachelez, Peter C M van de Kerkhof, Robert Strohal, Alexey Kubanov, Fernando Valenzuela, Joo-Heung Lee, Vladimir Yakusevich, Sergio Chimenti, Jocelyne Papacharalambous, James Proulx,[...]. Lancet 2015
263
13

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Gerd R Burmester, Ricardo Blanco, Christina Charles-Schoeman, Jürgen Wollenhaupt, Cristiano Zerbini, Birgitta Benda, David Gruben, Gene Wallenstein, Sriram Krishnaswami, Samuel H Zwillich,[...]. Lancet 2013
473
13

Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
William J Sandborn, Subrata Ghosh, Julian Panes, Ivana Vranic, Chinyu Su, Samantha Rousell, Wojciech Niezychowski. N Engl J Med 2012
539
13

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
Maurizio Cutolo, Gary E Myerson, Roy M Fleischmann, Frédéric Lioté, Federico Díaz-González, Filip Van den Bosch, Helena Marzo-Ortega, Eugen Feist, Kamal Shah, ChiaChi Hu,[...]. J Rheumatol 2016
119
13

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial.
Philip J Mease, Dafna D Gladman, David H Collier, Christopher T Ritchlin, Philip S Helliwell, Lyrica Liu, Gregory Kricorian, James B Chung. Arthritis Rheumatol 2019
93
13

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Christian E Antoni, Arthur Kavanaugh, Bruce Kirkham, Zuhre Tutuncu, Gerd R Burmester, Udo Schneider, Daniel E Furst, Jerry Molitor, Edward Keystone, Dafna Gladman,[...]. Arthritis Rheum 2005
485
13

Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
Roy Fleischmann, Aileen L Pangan, In-Ho Song, Eduardo Mysler, Louis Bessette, Charles Peterfy, Patrick Durez, Andrew J Ostor, Yihan Li, Yijie Zhou,[...]. Arthritis Rheumatol 2019
169
12

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.
Peter Nash, Laura C Coates, Alan J Kivitz, Philip J Mease, Dafna D Gladman, José A Covarrubias-Cobos, Oliver FitzGerald, Dona Fleishaker, Cunshan Wang, Joseph Wu,[...]. Rheumatol Ther 2020
27
44

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
Christopher J Edwards, Francisco J Blanco, Jeffrey Crowley, Charles A Birbara, Janusz Jaworski, Jacob Aelion, Randall M Stevens, Adele Vessey, Xiaojiang Zhan, Paul Bird. Ann Rheum Dis 2016
156
12

Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study.
Arthur Kavanaugh, M Elaine Husni, Diane D Harrison, Lilianne Kim, Kim Hung Lo, Jocelyn H Leu, Elizabeth C Hsia. Arthritis Rheumatol 2017
67
17

Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.
Philip J Mease, Alice B Gottlieb, Désirée van der Heijde, Oliver FitzGerald, Alyssa Johnsen, Marleen Nys, Subhashis Banerjee, Dafna D Gladman. Ann Rheum Dis 2017
121
12

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
Josef S Smolen, Aileen L Pangan, Paul Emery, William Rigby, Yoshiya Tanaka, Juan Ignacio Vargas, Ying Zhang, Nemanja Damjanov, Alan Friedman, Ahmed A Othman,[...]. Lancet 2019
144
11

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
Peter C Taylor, Edward C Keystone, Désirée van der Heijde, Michael E Weinblatt, Liliana Del Carmen Morales, Jaime Reyes Gonzaga, Sergey Yakushin, Taeko Ishii, Kahaku Emoto, Scott Beattie,[...]. N Engl J Med 2017
417
11

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Mark C Genovese, Roy Fleischmann, Bernard Combe, Stephen Hall, Andrea Rubbert-Roth, Ying Zhang, Yijie Zhou, Mohamed-Eslam F Mohamed, Sebastian Meerwein, Aileen L Pangan. Lancet 2018
204
11

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
Iain B McInnes, Frank Behrens, Philip J Mease, Arthur Kavanaugh, Christopher Ritchlin, Peter Nash, Jordi Gratacós Masmitja, Philippe Goupille, Tatiana Korotaeva, Alice B Gottlieb,[...]. Lancet 2020
88
12

Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis.
Adeline Ruyssen-Witrand, Richard Perry, Clare Watkins, George Braileanu, Gayathri Kumar, Sandeep Kiri, Debby Nott, Soyi Liu-Leage, Susanne Hartz, Christophe Sapin. RMD Open 2020
28
39


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.